456 related articles for article (PubMed ID: 25985771)
1. Predicting Effectiveness of Imatinib Mesylate in Tumors Expressing Platelet-Derived Growth Factors (PDGF-AA, PDGF-BB), Stem Cell Factor Ligands and Their Respective Receptors (PDGFR-α, PDGFR-β, and c-kit).
Moawad EY
J Gastrointest Cancer; 2015 Sep; 46(3):272-83. PubMed ID: 25985771
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genes.
Kadivar A; Kamalidehghan B; Akbari Javar H; Karimi B; Sedghi R; Noordin MI
Drug Des Devel Ther; 2017; 11():469-481. PubMed ID: 28260860
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
[TBL] [Abstract][Full Text] [Related]
6. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.
Brave SR; Ratcliffe K; Wilson Z; James NH; Ashton S; Wainwright A; Kendrew J; Dudley P; Broadbent N; Sproat G; Taylor S; Barnes C; Silva JC; Farnsworth CL; Hennequin L; Ogilvie DJ; Jürgensmeier JM; Shibuya M; Wedge SR; Barry ST
Mol Cancer Ther; 2011 May; 10(5):861-73. PubMed ID: 21441409
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
Roberts WG; Whalen PM; Soderstrom E; Moraski G; Lyssikatos JP; Wang HF; Cooper B; Baker DA; Savage D; Dalvie D; Atherton JA; Ralston S; Szewc R; Kath JC; Lin J; Soderstrom C; Tkalcevic G; Cohen BD; Pollack V; Barth W; Hungerford W; Ung E
Cancer Res; 2005 Feb; 65(3):957-66. PubMed ID: 15705896
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB.
Aoki M; Nabeshima K; Koga K; Hamasaki M; Suzumiya J; Tamura K; Iwasaki H
Lab Invest; 2007 Aug; 87(8):767-79. PubMed ID: 17558420
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
10. The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice.
Bäckman U; Christofferson R
Pediatr Res; 2005 May; 57(5 Pt 1):690-5. PubMed ID: 15718357
[TBL] [Abstract][Full Text] [Related]
11. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma.
Kim R; Emi M; Arihiro K; Tanabe K; Uchida Y; Toge T
Cancer; 2005 May; 103(9):1800-9. PubMed ID: 15786421
[TBL] [Abstract][Full Text] [Related]
12. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension.
Perros F; Montani D; Dorfmüller P; Durand-Gasselin I; Tcherakian C; Le Pavec J; Mazmanian M; Fadel E; Mussot S; Mercier O; Hervé P; Emilie D; Eddahibi S; Simonneau G; Souza R; Humbert M
Am J Respir Crit Care Med; 2008 Jul; 178(1):81-8. PubMed ID: 18420966
[TBL] [Abstract][Full Text] [Related]
13. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
Beppu K; Jaboine J; Merchant MS; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2004 Jan; 96(1):46-55. PubMed ID: 14709738
[TBL] [Abstract][Full Text] [Related]
14. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
[TBL] [Abstract][Full Text] [Related]
15. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
[TBL] [Abstract][Full Text] [Related]
16. Assessment of antiangiogenic effect of imatinib mesylate on vestibular schwannoma tumors using in vivo corneal angiogenesis assay.
Yener U; Avsar T; Akgün E; Şeker A; Bayri Y; Kılıç T
J Neurosurg; 2012 Oct; 117(4):697-704. PubMed ID: 22900848
[TBL] [Abstract][Full Text] [Related]
17. PDGF isoform-induced proliferation and receptor expression in human cultured airway smooth muscle cells.
Hirst SJ; Barnes PJ; Twort CH
Am J Physiol; 1996 Mar; 270(3 Pt 1):L415-28. PubMed ID: 8638734
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells.
Yamaguchi SI; Ueki A; Sugihara E; Onishi N; Yaguchi T; Kawakami Y; Horiuchi K; Morioka H; Matsumoto M; Nakamura M; Muto A; Toyama Y; Saya H; Shimizu T
Cancer Sci; 2015 Jul; 106(7):875-82. PubMed ID: 25940371
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma.
Katayama R; Huelsmeyer MK; Marr AK; Kurzman ID; Thamm DH; Vail DM
Cancer Chemother Pharmacol; 2004 Jul; 54(1):25-33. PubMed ID: 15108021
[TBL] [Abstract][Full Text] [Related]
20. Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells.
Uren A; Merchant MS; Sun CJ; Vitolo MI; Sun Y; Tsokos M; Illei PB; Ladanyi M; Passaniti A; Mackall C; Toretsky JA
Oncogene; 2003 Apr; 22(15):2334-42. PubMed ID: 12700668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
